Print

External Advisory Board

The External Advisory Board (EAB) members is broad representative of the scientific missions of GHUCCTS and consist of representatives from funded CTSA institutions in order to benefit from their experience with implementing CTSA programs at their institutions. One member each will overlap with the EABs named for the BioInformatics and Research, Education, Training and Career Development components. In addition, members have been solicited from government agencies responsible for clinical research and health care policy research in the Washington, DC region, national organizations involved with training and education, foundations and industries. The EAB consist of approximately 5 members, who will participate in semi-annual one-day, on-site meetings for the first 2 years of CTSA funding and in yearly meetings afterward. The primary goal of the on-site meetings will be to provide a general review of the GHUCCTS programs and goals, and to assess the degree to which milestones both for the overall program and each of its components have been achieved. These meetings will be planned and chaired by the Director of Tracking and Evaluation in consultation with the PIs. We anticipate both written and verbal presentations by the constituencies of the GHUCCTS and, in later years, targeted responses to questions that may be raised by the EAB at previous meetings.

Board Members:

William W. Chin, MD
Chief Medical Officer, Frequency Therapeutics
Bertarelli Professor Emeritus of Translational Medical Science, and Professor Emeritus of Medicine; Harvard Medical School
Former Executive Vice President, Science and Regulatory Advocacy; and Chief Medical Officer; Pharmaceutical Research and Manufacturers of America (PhRMA)

Dr. William W. Chin is Chief Medical Officer, Frequency Therapeutics and the former Executive Vice President for Science and Regulatory Advocacy and Chief Medical Officer at PhRMA (2013—2018). He was also the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS) from 2010—2013. In this role, Dr. Chin spearheaded efforts to design and implement the vision for research at HMS, with special emphasis on interdisciplinary and translational research that crosses departmental and institutional boundaries. Prior to this position, Dr. Chin was at Eli Lilly and Company, where he worked for over a decade starting in 1999, last as senior vice president for Discovery Research and Clinical Investigation. Chin is a Harvard-trained endocrinologist and longstanding faculty member. His career is exemplified in part by his extensive bibliography of nearly 300 papers, chapters and books, most of which were generated during his 25 years on the Harvard Medical School faculty. During his tenure as a faculty member in the Department of Medicine at Brigham and Women’s Hospital, he was chief of the Genetics Division and a Howard Hughes Medical Institute investigator and professor of medicine at HMS. As a pioneering molecular endocrinologist at HMS, Dr. Chin embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. His investigations often demonstrated a translational research theme, connecting basic laboratory discoveries to their physiologic relevance in animal models and humans. He has been honored with numerous awards for research, mentorship and leadership. Dr. Chin currently serves on the Board of Directors and Science Advisory Board of Regenacy Pharmaceuticals; SAB of Rhythm; Medical Advisory Board of Catabasis; and Board of Directors, A*STAR, Singapore. He received his AB from Columbia University and his MD from Harvard Medical School.

 

Daniel Ford, MD, MPH

Professor of Medicine, and Epidemiology and Health Policy and Management
Vice Dean for Clinical Investigation, School of Medicine;
Core Faculty, Welch Center for Prevention, Epidemiology, and Clinical Research
Johns Hopkins University

Dr. Daniel Ford is the David M Levine Professor of Medicine at Johns Hopkins. He received his M.D. from the State University of New York at Buffalo and came to Baltimore in 1982 to complete the Osler medicine residency at Johns Hopkins.  He received his master’s degree in public health from the Bloomberg School of Public Health in 1986 and completed a Clinical Epidemiology Fellowship at the National Institute of Mental Health before returning to Johns Hopkins.  He has published more than 160 research papers and book chapters focused primarily on the interrelationship of depression and chronic medical disorders.

In 2005, Dr. Ford was appointed as the Vice Dean for Clinical Investigation and Institutional Official overseeing human subjects research for the Johns Hopkins University School of Medicine.  He is the Principal Investigator for the Johns Hopkins Clinical and Translational Science Award (CTSA) from the NIH and was appointed the Director of the Institute for Clinical and Translational Research in 2007.

 

Julianne Imperato-McGinley, MD
Chief, Attending Professor, Endocrinology, Diabetes & Metabolism
Associate Dean for Translational Research and Education
Director and Principal Investigator for Clinical and Translational Science Center
Weill Cornell Medical College

Dr. Julianne L. Imperato-McGinley is recognized as one of this nation’s finest endocrinologists. After graduating from the College of Mount Saint Vincent she entered the State University of New York Downstate College of Medicine, earned the M.D., and began a career as a medical researcher in endocrinology.

In the 1970’s, she learned of a remote village in the Dominican Republic in which one group of people all appeared female at birth but developed into males at puberty. Additionally suggestive, none of these men ever developed prostate problems. There she began pioneering research that helps to explain the biological mechanisms of identity and personality. She was able to define the role of male hormones in normal human development. Her research directly led to the first medical therapy to remedy prostate enlargement, and subsequently (much to the joy of middle aged men everywhere) to the first treatment for male-pattern baldness. She related studies in androgen physiology and was the first to challenge the widely held view that gender is socially acquired and are now considered classic.

Today she is the Principal Investigator and Director for the largest federal research grant ever awarded to the Weil Cornell Medical College. There, she serves as Associate Dean for Translational Research and Education and is known for telling your students, “You have to think because sometimes the disease doesn’t read the textbook.” She has authored more than 130 papers in peer-reviewed journals. Much of her research is included as standard fare in textbooks on endocrinology, psychology and urology, and she is ranked among the world’s most respected medical researchers.

Julianne was an Ad Laudem Dei honoree 2008.

Michael Kahn, MD, PhD
Associate Professor, Department of Pediatrics, University of Colorado, Denver
Co-Director of the Colorado Clinical and Translational Sciences Institute (CCTSI)
Biomedical Informatics core director for the CCTSI Director of Clinical Informatics in the Department of Quality & Patient Safety at The Children’s Hospital
University of Colorado, Denver

Dr. Kahn is Associate Professor of Epidemiology in the Department of Pediatrics at the University of Colorado Denver, Co-Director of the Colorado Clinical and Translational Sciences Institute (CCTSI), Biomedical Informatics core director for the CCTSI and Director of Clinical Informatics in the Department of Quality & Patient Safety at The Children’s Hospital. Dr. Kahn holds joint appointments in the School of Medicine, School of Public Health, College of Nursing and Graduate School at the University of Colorado.

Dr. Kahn’s research interests include real-time clinical decision support linked to clinical outcomes monitoring, clinical data warehouses for both operational and retrospective research support, integration of electronic medical records with prospective research, and translational research informatics for both T1 (bench to bedside) and T2 (bedside to community) translational settings.

 

Wishwa Kapoor, MD, MPH
Falk Professor of Medicine, Professor of Health Policy and Management
Chief, Division of General Internal Medicine, Vice Chair, Department of Medicine
Director, Institute for Clinical Research Education, and Center for Research on Health Care
Co-Director, RAND-University of Pittsburgh Health Institute, and Clinical and Translational Science Institute, University of Pittsburgh

Dr. Kapoor has led major efforts in health services research, including research related to the outcomes and evaluation of syncope and the outcomes, cost, and quality of care for pneumonia. He directs the Center for Research on Health Care and the Institute for Clinical Research Education. He has extensive experience in mentoring fellows and junior faculty who have developed successful academic careers. Dr. Kapoor is a member of the ASCI and AAP, past president of the Society of General Internal Medicine, and chair of the Federal Council of Internal Medicine.

Emma A. Meagher, MD
Vice Dean and Chief Clinical Research Officer
Director, Clinical and Translational Research Training
Senior Associate Vice Provost, Human Research

Perelman School of Medicine, University of Pennsylvania

Emma A. Meagher, MD, serves as Professor of Medicine and Pharmacology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA. Dr. Meagher graduated cum laude with her medical degree from the Royal College of Surgeons in Dublin, Ireland, and completed postgraduate training in Internal Medicine, Cardiology and Pharmacology.

In her roles as Vice Dean and Chief Clinical Research Officer, and as Senior Associate Vice Provost for Human Research, Dr. Meagher oversees the institution’s clinical research infrastructure and its portfolio, and sets the strategy for Penn Medicine’s clinical research enterprise. In her role as Director of Clinical and Translational Research Training, Dr. Meagher is responsible for the institutions’ Master’s degree programs, certificate programs, annual workshops, and symposia directed at undergraduates; medical, dental and nursing students; pre-doctoral and postdoctoral trainees; and faculty in the Perelman School of Medicine, School of Nursing, School of Dental Medicine, School of Veterinary Medicine, and School of Engineering and Applied Science; in addition to educational curricula directed at clinical research support staff.

Dr. Meagher is certified as a Master Trainer via the NIH-funded National Research Mentoring Network (NRMN), and initiated the development of research mentor training at Penn in 2012. Developed out of a collaborative effort between Penn and The Children’s Hospital of Philadelphia (CHOP), with materials from the University of Wisconsin and the Penn Wharton business school, over 100 faculty from Penn and CHOP have participated to date. She has also successfully incorporated a Mentee Training curriculum for Master’s in Translational Research students.

Dr. Meagher’s research interests are in the development of novel therapeutics for dyslipidemia, and the evaluation of innovative educational methodologies for clinical and translational scientists. She currently serves as Co-PI for the Penn CTSA, PI of the KL2 and TL1 grants, and as Past-President of the Association for Clinical and Translational Science (ACTS) and chairs its Education Committee.

Wilkins Small.jpg

Consuelo H. Wilkins, MD, MSCI
Executive Director, Meharry-Vanderbilt Alliance
Associate Professor of Medicine, Vanderbilt University
Associate Professor of Medicine, Meharry Medical College

Consuelo H. Wilkins, MD, MSCI, is the Executive Director of the Meharry-Vanderbilt Alliance and Associate Professor of Medicine at both Vanderbilt University Medical Center and Meharry Medical College. As Associate Director of the Vanderbilt Institute for Clinical and Translational Science, she oversees programs in team science and community engagement. Dr. Wilkins is currently a Principal Investigator of the Vanderbilt-Miami-Meharry Center of Excellence in Precision Medicine and Population Health, which focuses on decreasing disparities among African Americans and Latinos using precision medicine, and the Vanderbilt Recruitment Innovation Center, a national center dedicated to enhancing recruitment and retention in clinical trials. She has pioneered methods of stakeholder engagement that involve community members and patients in research across the translational spectrum. Dr. Wilkins is leader of the Engagement Core of the All of Us Research Program (a component of the Precision Medicine Initiative) and an investigator in Meharry Clinical and Translation Research Center, the RCMI Program in Health Disparities Research at Meharry, and Mid-South Clinical Data Research Network.

Prior to her current role, Dr. Wilkins was an Associate Professor in the Department of Medicine, Division of Geriatrics, with secondary appointments in Psychiatry and Surgery (Public Health Sciences) at Washington University School of Medicine in St. Louis. She served as Founding Director of the Center for Community Health and Partnerships in the Institute for Public Health, co-director of the Center for Community Engaged Research in the CTSA, and director of "Our Community, Our Health"- a collaborative program with Saint Louis University to disseminate culturally relevant health information and facilitate community-academic partnerships to address health disparities.
Dr. Wilkins earned a Bachelor of Science in microbiology (magna cum laude, Phi Beta Kappa) and a Doctor of Medicine from Howard University. She completed residency training in Internal Medicine at Duke University Medical Center and a Geriatric Medicine fellowship at Washington University School of Medicine/Barnes-Jewish Hospital. Following her medical training, Dr. Wilkins earned a Master of Science in Clinical Investigation from Washington University School of Medicine.